Tag: RSV2
29 Percent of Infants Immunized Against RSV in 2023 to 2024 Season
Infant RSV immunization coverage through nirsevimab or maternal vaccination ranged from an estimated 11 to 53 percent by state
Nirsevimab Effective for Protecting Infants From RSV Lower Respiratory Tract Disease
Effectiveness seen for RSV lower respiratory tract disease, hospitalized RSV lower respiratory tract disease, PCR-confirmed RSV
Seniors With RSV-Linked Hospitalization Have Increased Cardiovascular Outcomes
Patients hospitalized with RSV have greater risk for subsequent heart failure events compared with patients with influenza, UTI, fracture
35 Percent of Eligible Children Receive RSV Prophylaxis With Nirsevimab
Older age, Black race, very low Child Opportunity Index, public insurance linked to lower rates of nirsevimab receipt
CDC Now Recommends RSV Vaccine for Some Adults 50+
By I. Edwards HealthDay Reporter
MONDAY, July 7, 2025 (HealthDay News) — Adults as young as 50 may now qualify for an RSV vaccine if...
New Antibody Shot Could Help Protect Babies From RSV
By I. Edwards HealthDay Reporter
THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial virus...
Odds of Cardiovascular Events Up for RSV Hospitalization Versus COVID-19 Hospitalization
Odds of any acute cardiovascular event increased when compared with COVID-19 hospitalizations in boosted and unboosted individuals
